FindTrial
Sign In

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

Predictive Value of Pretreatment Peripheral Neutrophil-to-Lymphocyte Ratio for Response to Neoadjuvant Chemotherapy and Breast Cancer Prognosis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000034559
Enrollment
Unknown
Registered
2020-07-10
Start date
2020-08-01
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

Case series:none

Sponsors

West China hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
Male

Inclusion criteria

Inclusion criteria: (1) diagnosed as primary breast cancer by core needle biopsy before NAC; (2) female and clinical stage I-III; (3) received NAC and subsequent mastectomy or breast-conserving surgery.

Exclusion criteria

Exclusion criteria: (1) inflammatory breast cancer; (2) stage IV disease; (3) pregnancy-associated breast cancer.

Design outcomes

Primary

MeasureTime frame
Neutrophil-to-lymphocyte ratio;Lymph node ratio;—

Countries

China

Contacts

Public ContactYang Xiaoqin

West China Hospital, Sichuan University

xiaoqinyang2019@outlook.com+86 18980605792

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026